Professor Marek Lubusky, MD, PhD, MHAProfessor Marek Lubusky, MD, PhD, MHA

Durdová V., Holusková I., Kratochvílová T., Strašilová P., Ľubušký M. Klinický význam neinvazivního stanovení KEL genotypu plodu v managementu těhotenství s rizikem rozvoje hemolytické nemoci plodu a novorozence. Postgrad. Med. 2016, 18 (4), s. 358-361. (The clinical significance of the non-invasive fetal KEL genotype assessment in the management of pregnancies at risk of hemolytic disease of the fetus and newborn)

ABSTRACT

In the Czech Republic, all pregnant women in their 1st trimester undergo the red blood cell antibody screening. The clinically significant alloantibody anti-K (Kell, KEL1) is diagnosed in about 0.1% of women (100 women a year in the Czech Republic). However, the fetuses are at risk of hemolytic disease only if the complementary antigen is present on their erythrocytes. This is the case of about 5% of them (5 fetuses a year) in contrast to 95% of them (95 fetuses a year) lacking the complementary antigen and thus not at risk of Hemolytic Disease of the Fetus and Newborn. The presence of the complementary antigen can be assessed noninvasively by KEL genotyping from cell-free fetal DNA circulating in the peripheral blood of pregnant women.


ULTRAZVUK V PORODNICTVÍ A GYNEKOLOGII | portál Sekce ultrazvukové diagnostiky ČGPS ČLS JEP Moravská konference fetomaternální medicíny Olomouc
Fulltext search
 

Contact

Professor Marek Lubusky, MD, PhD, MHA

THE FETAL MEDICINE CENTRE
Department of Obstetrics and Gynecology
Palacky University Olomouc, Faculty of Medicine and Dentistry
University Hospital Olomouc
I. P. Pavlova 6, 77520 Olomouc, Czech Republic
Tel: +420 585 852 785
Mobil: +420 606 220 644
E-mail: marek@lubusky.com
Web: www.lubusky.com


Contact form
NAME
E-MAIL
MESSAGE
 
© ESMEDIA a.s.